Mission Wealth Management LP Has $3.56 Million Stock Position in Edwards Lifesciences Corporation $EW

Mission Wealth Management LP boosted its stake in Edwards Lifesciences Corporation (NYSE:EW) by 2.4% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 45,530 shares of the medical research company’s stock after buying an additional 1,073 shares during the quarter. Mission Wealth Management LP’s holdings in Edwards Lifesciences were worth $3,561,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of EW. Econ Financial Services Corp acquired a new position in shares of Edwards Lifesciences during the 2nd quarter worth about $889,000. Allspring Global Investments Holdings LLC increased its position in Edwards Lifesciences by 0.5% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 30,195 shares of the medical research company’s stock worth $2,170,000 after buying an additional 145 shares during the period. Pacific Capital Partners Ltd acquired a new position in shares of Edwards Lifesciences during the second quarter worth approximately $1,760,000. Czech National Bank boosted its position in shares of Edwards Lifesciences by 5.8% in the second quarter. Czech National Bank now owns 143,385 shares of the medical research company’s stock valued at $11,214,000 after acquiring an additional 7,917 shares during the period. Finally, Mirova US LLC boosted its position in shares of Edwards Lifesciences by 56.2% in the second quarter. Mirova US LLC now owns 2,931,297 shares of the medical research company’s stock valued at $229,257,000 after acquiring an additional 1,054,301 shares during the period. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on EW shares. Morgan Stanley upped their target price on shares of Edwards Lifesciences from $75.00 to $81.00 and gave the company an “equal weight” rating in a research note on Tuesday, July 15th. JPMorgan Chase & Co. boosted their price target on Edwards Lifesciences from $85.00 to $90.00 and gave the company a “neutral” rating in a research note on Friday. William Blair upgraded Edwards Lifesciences to a “strong-buy” rating in a research report on Friday, July 25th. Piper Sandler restated an “overweight” rating and set a $95.00 price objective (up from $90.00) on shares of Edwards Lifesciences in a research report on Friday. Finally, The Goldman Sachs Group set a $104.00 target price on Edwards Lifesciences and gave the company a “buy” rating in a research note on Friday. Three analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Edwards Lifesciences has a consensus rating of “Moderate Buy” and a consensus price target of $91.00.

Edwards Lifesciences Trading Down 1.2%

EW stock opened at $82.48 on Monday. Edwards Lifesciences Corporation has a 1-year low of $64.89 and a 1-year high of $87.09. The company has a current ratio of 4.68, a quick ratio of 3.87 and a debt-to-equity ratio of 0.06. The business’s 50 day moving average is $77.58 and its 200-day moving average is $76.97. The firm has a market cap of $48.42 billion, a P/E ratio of 11.87, a P/E/G ratio of 3.97 and a beta of 1.05.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, October 30th. The medical research company reported $0.67 EPS for the quarter, topping the consensus estimate of $0.59 by $0.08. The business had revenue of $1.55 billion during the quarter, compared to the consensus estimate of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.Edwards Lifesciences’s revenue was up 14.7% on a year-over-year basis. During the same quarter last year, the company earned $0.67 EPS. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS. Q4 2025 guidance at 0.580-0.640 EPS. Equities analysts anticipate that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Larry L. Wood sold 8,950 shares of the business’s stock in a transaction on Monday, August 18th. The shares were sold at an average price of $78.06, for a total value of $698,637.00. Following the sale, the insider owned 206,900 shares in the company, valued at approximately $16,150,614. The trade was a 4.15% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 1.29% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.